| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10025467 | HBV | ENSG00000070019.5 | protein_coding | GUCY2C | No | No | 2984 | P25092 |
| TVIS20050666 | HPV | ENSG00000070019.5 | protein_coding | GUCY2C | No | No | 2984 | P25092 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GUCY2C |
|---|---|
| DrugBank ID | DB08890 |
| Drug Name | Linaclotide |
| Target ID | BE0003502 |
| UniProt ID | P25092 |
| Regulation Type | agonist |
| PubMed IDs | 23090647; 24433216 |
| Citations | Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, Solinga RM, Tobin JV, Wakefield JD, Kurtz CB, Currie MG: Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther. 2013 Jan;344(1):196-206. doi: 10.1124/jpet.112.199430. Epub 2012 Oct 22.@@Layer P, Stanghellini V: Review article: Linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014 Feb;39(4):371-84. doi: 10.1111/apt.12604. Epub 2014 Jan 16. |
| Groups | Approved |
| Direct Classification | Polypeptides |
| SMILES | [H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL3301675 |
